Abnormal concentrations of inflammatory markers detected in children with B-cell precursor acute lymphoblastic leukemia (ALL) support the theory that children with ALL are born with dysregulated immune function.
Abnormal concentrations of inflammatory markers detected in children with B-cell precursor acute lymphoblastic leukemia (ALL) support the theory that children with ALL are born with dysregulated immune function.
The etiology of childhood ALL has been of interest for some time, but it has been inadequately analyzed. In the past, there was an assumption, the delayed infection hypothesis, that held that a lack of infections in early childhood caused abnormal immune responses later, leading to the transformation of preleukemic cells to leukemia.
However, this hypothesis has been challenged multiple times based on inconsistencies from epidemiologic studies. At present, there is a newer theory proposing that children with ALL are born with abnormal immune function, resulting in numerous infections during the first year of life. A previous study by Chang et al showed differences in inflammatory markers between children with ALL and children serving as controls. Recently, Signe Holst Søegaard, MSc, PhD fellow in the Department of Epidemiology Research at Statens Serum Institute in Copenhagen, Denmark, and colleagues sought to strengthen the connection between neonatal inflammatory markers and childhood ALL.
In the study, Søegaard and colleagues matched 178 children with B-cell precursor ALL with 178 controls. Patients in both groups had dried blood spot samples collected to analyze 9 different inflammatory markers: sIL6Rα, TGFβ1, MCP-1, CRP, IL6, IL8, IL12, IL17, andIL18.
Among the 9 inflammatory markers, 8 of them had statistically significant differences between the 2 groups. Neonatal concentrations of sIL6Rα, IL8, TGFβ1, MCP-1, and CRPwere all significantly lower in the B-cell precursor ALL group compared with the control group. In contrast, IL6, IL17, and IL18were all significantly higher in the B-cell precursor ALL group compared with the control group.
When observing for any baseline characteristics that affected inflammatory marker concentrations, investigators found that birth order, gestational age, and sex were linked with significant changes. Higher birth orders led to a significantly higher IL18and a significantly lower CRPconcentration. Increasing gestational age was associated with a 5% lower sIL6Rαconcentration, and a 4% lower TGFβ1concentration. Gender discrepancies also revealed boys to have 9% lower sIL6Rαconcentration, 8% lower IL8concentration, and 22% higher CRPconcentration than girls.
This study and the previous study by Chang et al support the hypothesis of an abnormal immune function in children with ALL. Because the dysfunction in immune function is detectable at birth, there is opportunity “for the prevention of childhood ALL through early immune modulation,” Søegaard saidin a statement. Additional inflammatory markers and risk factors of ALL should be investigated in future studies.
Reference
Søegaard S, Rostgaard K, Skogstrand K, Wiemels JL, Schmiegelow K, Hjalgrim H. Neonatal inflammatory markers are associated with childhood B-cell precursor acute lymphoblastic leukemia. Cancer Res. 2018;78(18):5458-5463. doi: 10.1158/0008-5472.CAN-18-0831.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen